Study 17 of 594 for search of: received on or after 01/16/2009
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Thyroid Function Throughout Pregnancy With and Without Iodine Supplementation
This study has been completed.
Sponsored by: Centre Hospitalier Universitaire de Nice
Information provided by: Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier: NCT00831402
  Purpose

Goals of the study :

  1. To study maternal thyroid function during pregnancy with or without supplementation with pregnancy tablets fortified with iodine
  2. To establish reference values of thyroid function at different stages of pregnancy (3 trimesters)
  3. To precise screening strategy of iodine deficiency in our population and suggest recommendation for its prevention.

Condition Intervention
Pregnancy
Dietary Supplement: Oligobs Maxiode

Drug Information available for: Iodine Cadexomer iodine Thyroid
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Assessment of Thyroid Function Throughout Pregnancy With and Without Iodine Supplementation

Further study details as provided by Centre Hospitalier Universitaire de Nice:

Primary Outcome Measures:
  • • Intra individual variation of maternal thyroglobulin between the first trimester and the delivery • And cord blood thyroglobulin With comparison of the 2 groups (control and supplementation with iodine) [ Time Frame: Every 3 months up to the give birth, the day of a give birth, and after three months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Comparison of control and treated groups for : • Frequence of miscarriage, duration of gestation, birth weight, APGAR, neonatal complications, Maternal thyroid function, Frequency of post partum thyroiditis,Cord blood thyroid function [ Time Frame: Every 3 months up to the give birth, the day of a give birth, and after three months ] [ Designated as safety issue: No ]

Enrollment: 111
Study Start Date: June 2007
Study Completion Date: August 2008
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Arm without iodized vitamin (VITAMIN OLIGOBS PREGNANCY): No Intervention
50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
Arm with iodized vitamin: Active Comparator
The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
Dietary Supplement: Oligobs Maxiode

Detailed Description:

Overt maternal hypothyroidism and/or iodine deficiency during pregnancy are linked to mental retardation in their offspring. Iodine deficiency may lead to maternal hypothyroxinemia, and even mild hypothyroidism in predisposed women. Indeed, thyroid hormones are of paramount importance for fetal brain development. During the first trimester of pregnancy, the only thyroid hormones available to the fetus are from maternal origin. Later in pregnancy, fetal thyroid progressively starts producing thyroid hormone, providing that maternal iodine status is adequate (≥200-250 mcg/day). It has been shown recently that mild maternal hypothyroidism may be responsible for discrete neuropsychological impairment in her child, implying a potential benefit for early screening and care during pregnancy. Furthermore, iodine deficiency is extremely common in our area (Brucker-Davis et al 2004). However, there is no official recommendation for screening and prevention, as for gestational diabetes for example.

We propose to study healthy pregnant women, screened before 12 weeks of gestation and without thyroid disease. They will be randomized in 2 groups and will therefore take pregnancy tablets, iodine fortified or not (Oligobs Maxiode -150 mcg/j of iodine, vs Oligobs grossesse), in addition to appropriate nutritional advice. Their longitudinal study will involve:

  1. Evolution of thyroid function parameters in the 2 groups, with comparison of maternal thyroid volumes, maternal thyroid hormones levels and cord blood parameters, including thyroglobulin, during pregnancy and in postpartum.
  2. Establishment of reference ranges for thyroid parameters for each trimester of pregnancy.

This public health project rests on our expertise in the care of pregnancies with maternal endocrine and metabolic disease (Hieronimus et al 2003-2005) and on a close collaboration of our Departments within the Pole "Mother-Child", conveniently located at the same hospital. It will allow us to precise iodine deficiency screening and prevention in our population and to structure and optimize the care for women with thyroid disease screened early in pregnancy (opening of a specific clinic), in order to improve maternal and fetal prognosis

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All women follow-up in the three months of the pregancy in the CHU de Nice
  • Maternal thyroid function is between and 0.1<TSH<2.5 mUI/l, 23>T4L>12 pmol/l
  • Person over 18
  • signed lit Consent
  • give birth in the CHU of Nice

Exclusion Criteria:

  • allergy known in iodine
  • iodized surcharge defined by an iodurie> 400 mcg / l
  • catch of ongoing iodized vitamins of pregnancy
  • participation in another research protocol
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00831402

Locations
France, Alpes-Maritimes
CHU de Nice - 4 avenue Reine Victoria - Hôpital de Cimiez
Nice, Alpes-Maritimes, France, 06001
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nice
Investigators
Principal Investigator: Françoise Dr BRUCKER-DAVIS, PH CHU de Nice - Service d'endocrinologie - Hôpital de l'Archet - 151 Route de saint-antoine de ginestière 06200 Nice
  More Information

Study ID Numbers: 05-PHRC-03
Study First Received: January 28, 2009
Last Updated: January 28, 2009
ClinicalTrials.gov Identifier: NCT00831402  
Health Authority: France: Direction Générale de la Santé

Keywords provided by Centre Hospitalier Universitaire de Nice:
woman

Study placed in the following topic categories:
Iodine

ClinicalTrials.gov processed this record on January 30, 2009